ARCHIVES

Second-Generation CML Drugs Show Promise For Frontline

This article is from The Cancer Letter archive.

Vol. 31 No. 12 | December 26, 2008

Download PDF Visit The Full Archive

Related Articles

News Analysis: Filing Will Ignite Complex Litigation Costing Millions, With Uncertain Rewards

March 9, 2012

NALSO Members Urged To Police Selves, Adopt Ethics Code

August 4, 1978

NCI Plans Trials of Burzynski’s ‘Antineoplaston’; JAMA Report Says No Antitumor Activity In Tests

June 5, 1992

ASCO: NCI Authorities Still Important

June 11, 2010

Docetaxel, Oxaliplatin Active Against Esophageal Cancer

June 30, 2006

Nominations sought for NCI consumer liaison group.

January 9, 2004